Compare BIO-TECHNE Corp (TECH) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.51. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| TECH | VNQI | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | — |
52-Week High | $72.29 | $50.76 |
52-Week Low | $43.31 | $43.26 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
VNQI, the Vanguard Global ex-U.S. Real Estate ETF, trades at $46.23, up 0.72% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides diversified exposure to international real estate markets across more than 30 countries, featuring a low expense ratio and higher dividend yield compared to U.S.-focused peers, though recent performance has lagged domestic alternatives in total returns.
The outlook for VNQI hinges on global real estate recovery and currency movements, offering yield and diversification benefits amid geopolitical and economic risks. Key risks include foreign market volatility and interest rate sensitivity, while analyst sentiment is mixed due to weaker historical returns versus U.S. counterparts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
